

BioMimetic Product Sales Statement

As previously certified in our Product Sales Statement for, and as of, the twelve month period ended February 24, 2019, trailing twelve month product sales of Augment Bone Graft and Augment Injectable were \$42.5 million during such period. Product sales during the immediately following five day period February 25, 2019 through March 1, 2019 were insufficient, as of any of such five days, to increase trailing twelve month sales from \$42.5 million to \$70 million. Therefore, the second sales milestone of \$70 million was not achieved prior to expiration of the Contingent Value Rights Agreement (CVR Agreement) between Wright Medical Group, Inc. and American Stock Transfer & Trust Company dated March 1, 2013 on March 1, 2019. Accordingly, no further milestone payment is owed under the CVR Agreement.

/s/ Lance A. Berry
Executive Vice President,
Chief Financial and Operation Officer
April 16, 2019